Humacyte, Inc. (HUMA) Stock

Humacyte, Inc. (HUMA) is a Healthcare stock trading at $0.71 (as of 2026-08-06), with a market capitalization of $164.24M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Humacyte, Inc. develops and manufactures human acellular vessels and related implantable human tissues using its technology platform. These investigational products are intended for implantation across therapeutic areas such as vascular repair and reconstruction, with applications including vascular trauma, hemodialysis access, and peripheral arterial disease, and other uses in pediatric surgery and cellular therapy delivery.

Valuation — source: SEC EDGAR (first-party)
Price$0.71
Market Cap$164.24M
DCF Value (model)$-7.22
DCF Upside vs Price-1120.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.97 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($8.09M)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryBiotechnology
CEOLaura E. Niklason
Employees218
CountryUS
IPO Date2020-12-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Coherus Oncology, Inc. (CHRS)
  • Voyager Therapeutics, Inc. (VYGR)
  • Protalix BioTherapeutics, Inc. (PLX)
  • Armata Pharmaceuticals, Inc. (ARMP)
  • Caribou Biosciences, Inc. (CRBU)
  • Invivyd, Inc. (IVVD)
  • LENZ Therapeutics, Inc. (LENZ)
HUMA earnings history · HUMA institutional & insider holders · HUMA KPIs & operating metrics · HUMA financials · HUMA investor presentations & press releases · HUMA SEC filings · HUMA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-06.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.